NSWRC(SH:600165) Xin Lang Cai Jing·2025-12-19 07:48Core Viewpoint - The article discusses the legal progress regarding investor compensation claims against Ningke Biological (600165) due to false statements in financial reporting and failure to disclose significant events [1][5]. Group 1: Legal Developments - On December 18, 2025, significant progress was made in the investor compensation case against Ningke Biological, with some investors receiving compensation [1]. - The law firm representing the investors has filed additional claims in court [1]. - A court ruling has been received, confirming that investors have won their case [1]. Group 2: Regulatory Findings - On April 4, 2024, Ningke Biological announced that it received an administrative penalty decision from the Ningxia Regulatory Bureau of the CSRC, confirming violations [5]. - The company inflated its 2022 revenue by 76.5941 million yuan and profit by 77.222 million yuan, representing 11.25% and 46.59% of total revenue and profit, respectively [5]. - The company failed to timely disclose significant events, including major debts, frozen bank accounts, and the suspension of key subsidiary operations [2][3][4]. Group 3: Investor Compensation Eligibility - Investors who purchased Ningke Biological shares between November 22, 2022, and April 6, 2023, and sold or held shares after April 6, 2023, are eligible for compensation [7]. - Additionally, investors who bought shares between April 28, 2023, and October 31, 2024, and sold or held shares after October 31, 2024, can also initiate claims [7].